Contineum Therapeutics joined the 2024 initial public offering class on Friday with an SEC filing. The biotech will use the IPO proceeds to complete a Phase II trial for its most mature candidate targeting multiple sclerosis.
Tag Archive for: immunology
The British drugmaker said it sold around 300 million shares of Haleon, cutting its shareholding to 4.2%, as it expands its portfolio of specialty medicines.
Mergers and acquisitions across the pharmaceuticals and life sciences sector will reach a “healthy” level next year, with deals totaling $225 billion to $275 billion, according to professional services firm PwC’s new US Deals 2024 Outlook report.
In an R&D event on Thursday, the French pharma is trying to win over its investors by highlighting a dozen potential blockbusters and charting strong growth for the company through 2030.
The deal is aimed at speeding up the development of therapeutics in areas including oncology, immunology and rare diseases.
Eli Lilly and Co. agreed to buy Dice Therapeutics Inc. for about $2.4 billion in cash on Tuesday, bolstering its immune disease-related portfolio with a largely oral drug developer.
The company said the focus of its drug research would shift away from women’s health, a traditional pillar of Germany’s largest drugmaker, to hone in on neurology, rare diseases and immunology.
The combined capabilities will help improve trial lifecycles for patients, sites, and sponsors.
